Ignite Creation Date:
2025-12-25 @ 2:47 AM
Ignite Modification Date:
2026-03-09 @ 9:20 AM
Study NCT ID:
NCT00528333
Status:
COMPLETED
Last Update Posted:
2015-01-07
First Post:
2007-09-10
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML
Sponsor:
Seagen Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
SG033-0003
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None